Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis

Dongdong Yuan; Xiangfen Shi; Liping Guo; Gaobiao Wang; Yujie Zhao; Yuling Yang; Hanjuan Zhang; Qiong Huang; Yiqiang Yuan

doi:10.12659/MSM.923758

16 June 2020 : Clinical Research

Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis

Dongdong Yuan^1ABCD, Xiangfen Shi^2BCD, Liping Guo^1BF, Gaobiao Wang^1BF, Yujie Zhao^1B, Yuling Yang^1B, Hanjuan Zhang^1B, Qiong Huang^1B, Yiqiang Yuan^1AE*

DOI: 10.12659/MSM.923758

Med Sci Monit 2020; 26:e923758

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Patients’ demographic data.

	Bleeding patients (n=25)	Non-bleeding patients (n=25)	P
Age (year)	64.00±10.76	59.59±12.98	0.227
Platelet (10/L)	273.35±122.6	224.05±85.65	0.135
Total cholesterol (mmol/L)	3.42±1.09	4.03±1.2	0.123
Prothrombin time (s)	9.75±0.91	10.06±1.00	0.346
Body mass index (kg/m)	24.88±3.32	25.06±2.89	0.853
Alanine transaminase (IU/L)	41.77±30.47	41.0±23.13	0.925
Aspartate transaminase (IU/L)	35.36±29.00	31.64±20.06	0.623
Activated partial thromboplastin time (s)	35.12±11.38	29.33±7.46	0.081

Back to the Article

Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis

Your Privacy